AffaMed is a late clinical-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs in ophthalmology. self-described.

AffaMed

AffaMed Therapeutics | 1,440 followers on LinkedIn. To Become a Leading Ophthalmology and CNS Company with Innovative Therapeutics and Solutions for China and the World. | AffaMed Therapeutics is a clinical stage therapeutic company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development at leading multi-national pharmaceutical companies in China and globally.

Innovation & Digital Health

Lingyun (Wendy) Mao

Director of Clinical Operation

Roger Liu

Research in opthalmology

Annie Yang

Chief Regulatory Officer, Global Regulatory Science - AffaMed Therapeutics (a Biotech company)

Rose Yu

AffaMed Therapeutics

As the first NDA filing by AffaMed Therapeutics , the acceptance of our DEXTENZA NDA in Singapore represents an important milestone in our company’s journey. AffaMed is developing DEXTENZA as the first physician-administered sustained-release intracanalicular insert available to patients in the ASEAN countries and Greater China for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. For more information please visit : https://lnkd.in/gRrgAKu8 #ophthalmology #cataract #allergicconjunctivitis

Happy Chinese New Year！ AffaMed Therapeutics wishes all our friends and relationships health, wealth and happiness in the new Year of the Dragon! 新春快乐！蔼睦医疗恭祝您和您的家人龙行大运，平安喜乐！

AFFA

COM:AFFAMED

AffaMed